By Daniella Parra Brii Biosciences and VBI Vaccines (NASDAQ: VBIV) said they will expand and control of BRII-179 supplies, a late-stage asset for HBV functional cure. Initially, a $2.5 million promissory note will be issued, eliminating royalty and milestone payments...

IPO Edge hosted a fireside chat from the floor of the New York Stock Exchange with Jeffrey Jakubiak, partner at Vinson & Elkins. Mr. Jakubiak spoke to Editor-in-Chief John Jannarone about the company’s forecast for 2024 regarding the FERC’s decisions...

By Carola McGiffert The U.S. government through successive administrations has sought to keep China from developing and manufacturing advanced technologies. The wisdom of clamping down on freely flowing trade around the world can be debated, but it would be an...

By Daniella Parra Agendia said it has enrolled the first patient using MammaPrint for the Oncology De-Escalation of Breast Radiation (DEBRA) Trial, aiming to reduce breast radiation post-lumpectomy for low-risk, early-stage breast cancer. The trial aims to determine whether hormonal...

By Daniella Parra Vaxxinity, Inc. (Nasdaq: VAXX) said it’s with the University of Florida’s Center for Translational Research in Neurodegenerative Disease (CTRND) to develop vaccines for diseases like Alzheimer’s and Parkinson’s. The collaboration aims to understand and neutralize toxic brain...

  Tech Edge and the Palm Beach Hedge Fund Association will host a fireside chat with Zapata AI on Jan. 31 at 10am ET. The live event will feature Christopher Savoie, Chief Executive Officer and co-founder, and Bill Sandbrook, Co-CEO...

By Exec Edge Editorial Staff Thank you both for joining me today. Let’s start with a little about yourselves and your organizations. Can you tell our readers a little about Aeries and Alegeus? Ajay: Of course – my name is...

By Karen E. Roman Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors. The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle  formulation,...

By Daniella Parra Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) said it showed additional safety and tolerability data, marking the second positive Phase 3 study assessing TNX-102 SL for fibromyalgia management. Tonix said the study met its primary endpoint, demonstrating statistically...

Exec Edge hosted a fireside chat at the 2024 ICR Conference with TRAY’s CEO and Founder Peter Kellis and its Chief Revenue Officer Brian Whitney. The in-person interview was joined by Editor-at-Large Jarrett Banks and they discussed the company’s expansion plans and how...